Results

1–7 of 7 results for David M. Brown

Efficacy and Safety of CT-P42 Compared to Reference Aflibercept (AFL) in Diabetic Macular Edema (DME): 24-Week Results From the Phase 3 CT-P42 3.1 Study
David M. Brown, MD
Annual Meeting Talks
2023
Brolucizumab for the Treatment of Visual Impairment Due to Diabetic Macular Edema: 52-Week Results From the KESTREL and KITE Studies
David M. Brown, MD
Annual Meeting Talks
2021
Suprachoroidal CLS-AX (axitinib injectable suspension), as a Potential Long-Acting Therapy for Neovascular Age-Related Macular Degeneration (nAMD)
David M. Brown, MD
Annual Meeting Talks
2020
How to Determine Posterior Vitreous Detachment Status With a 10-Second Retinal Nerve Fiber Layer Scan and Patient Age
David M. Brown, MD
Updates from the Field
2021
Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KITE and KESTREL studies
David M. Brown, MD
Updates from the Field
2021
Brolucizumab in HAWK/HARRIER: Outcomes, Efficacy, & Dosing Status – Everything You Need to Know!
David M. Brown, MD
Updates from the Field
2018
MACRA, MIPS, and Meeting Quality Measures
David M. Brown, MD
Updates from the Field
2017